DIABETES CARE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Diabetes Care Market Size and Forecast – 2025 to 2032

The diabetes care market is estimated to be valued at USD 34.51 Bn in 2025 and is expected to reach USD 62.73 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 8.9% from 2025 to 2032.

To learn more about this report, Download Free Sample

Key Takeaways

• Based on Product Type, Glucose Monitoring Device segment is projected to account for 47.7% of the global market in 2025, owing to its rapid advancements in technology.
• On the basis of Diabetes Type, Type 2 Diabetes segment to capture 66.2% share in 2025, owing to its rapidly rising prevalence globally. 
• By End User, the Hospitals & Clinics segment to hold 54.7% share in 2025, driven by their crucial role in diabetes care delivery.
• Regionally, North America is set to hold dominating position in the global diabetes care market with a 43. 1% share in 2025.

Market Overview

The diabetes care market is growing because a rising number people suffering from diabetes, especially type 2, which is linked to being inactive and being overweight. Also, the demand for new devices is growing because of improvements in technology and more people knowing how to manage diabetes.

Current Events and Its Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Role of AI (Artificial Intelligence) in Diabetes Care

Artificial intelligence (AI) plays a transformative role in diabetes care by enabling personalized, data-driven management. AI algorithms analyze continuous glucose monitor (CGM) data, lifestyle factors, and medical history to provide real-time insights and predictive alerts, helping users prevent highs and lows. It supports clinicians with decision-making tools, automates insulin dose recommendations, and enhances early detection of complications. AI also powers virtual coaching and adaptive learning systems that tailor guidance to individual needs.

In August 2025, GlucoSense launched the Companion feature in its Version 2.0 app update—an AI-powered tool that transforms CGM data into real-time, personalized insights, reinforcing its commitment to patient-centered diabetes management.

Segmental Insights

To learn more about this report, Download Free Sample

Diabetes Care Market Insights, by Product Type - Evolution of Technology Drives Demand for Glucose Monitoring Devices

In terms of product type, glucose monitoring devices segment is estimated to contribute the highest market diabetes care market share of 47.7% in 2025, driven by rapid advancements in technology. Continuous innovations are enhancing the design of testing strips, lancets, and meters, making blood sampling less painful and more convenient for users.

For instance, in August 2024, Abbott collaborated with Medtronic on an integrated continuous glucose monitoring (CGM) system based on Abbott's most advanced, world-leading¹ FreeStyle Libre technology that will connect with Medtronic's automated insulin delivery (AID) and smart insulin pen systems.

Diabetes Care Market Insights, by Diabetes Type - Growing Prevalence of Type 2 Diabetes Catalyzes Market Demand

In terms of diabetes type, type 2 diabetes is estimated to contribute the highest market share of 66.2% in 2025, owing to its rapidly rising prevalence globally. Type 2 diabetes incidence is increasing at an alarming rate mainly due to lifestyle related risk factors like obesity, physical inactivity, and unhealthy diets. Urbanization and aging populations have further aggravated the risk. It is estimated that over 90% of diabetic patients have type 2 diabetes worldwide.

For instance, in September 2025, Tandem Diabetes Care announced publication showing adults with type 2 diabetes benefit from automated insulin delivery regardless of c-peptide levels.

Diabetes Care Market Insights, by End User - Role of Hospitals & Clinics in Service Delivery and Patient Management

In terms of end user, hospitals & clinics segment is estimated to contribute the highest market share of 54.7% in 2025, driven by their crucial role in diabetes care delivery and comprehensive patient management. As the primary healthcare settings for diabetes patients, these facilities continuously enhance their service offerings to strengthen diabetes management infrastructure. This trend reflects the increasing demand for effective diabetes care solutions, as hospitals and specialty clinics adapt to the growing prevalence of diabetes and the need for advanced treatment options.

Regional Insights

To learn more about this report, Download Free Sample

Dominating Region: North America

North America is expected to dominate the diabetes care industry with the highest market share of 43.1% in 2025, due to supportive healthcare policies promoting preventive care, high consumer awareness about diabetes management, and presence of leading medical device companies.          

For instance, in September 2024, Abbott introduced over-the-counter continuous glucose monitoring system, Lingo, in the U.S. This innovative system allows consumers to track their glucose levels without a prescription, utilizing Abbott's advanced FreeStyle Libre technology. Lingo provides real-time glucose data and insights through a mobile app, empowering users to manage their health and wellness more effectively.

Fastest-Growing Region: Asia Pacific

Asia Pacific exhibits the fastest growth with 19.9% market share in 2025 in the diabetes care industry, due to the rising geriatric population susceptible to diabetes. Economic development in countries like China and India has improved access to diabetes care services and devices.

For instance, in August 2025, Abbott announced the launch of the FreeStyle Libre 2 Plus sensor, Abbott’s latest addition to the FreeStyle Libre sensor portfolio. FreeStyle Libre 2 Plus is now available across India for adults and children aged 2 and above, including women with gestational diabetes.

Diabetes Care Market Outlook for Key Countries

Well-established healthcare infrastructure in the U.S.

The U.S. diabetes care industry is characterized by a well-established healthcare infrastructure and a robust reimbursement system that supports effective diabetes management. Key players like Abbott Laboratories have solidified their positions in the insulin delivery segment, leveraging advanced technologies to enhance patient care and improve outcomes. Their innovative products, including insulin pumps and continuous glucose monitoring systems, are integral to managing diabetes effectively, addressing the growing prevalence of the condition in the population.

Growing medical needs in China

China’s diabetes care industry presents immense opportunities, driven by the growing medical needs of its large diabetic population. Local manufacturers are introducing affordable product options to cater to middle-income groups, enhancing accessibility and addressing the rising prevalence of diabetes. This focus on affordability and innovation is crucial for improving diabetes management across diverse socioeconomic segments in the country.

For instance, in June 2024, China's National Medical Products Administration approved Novo Nordisk's, which further opens new tab insulin icodec injection used for the treatment of Type-2 diabetes among adults to enter the Chinese market.

Growing prevalence of diabetes in India

India continues to lead in insulin usage, primarily due to increasing awareness and the availability of biosimilar insulin analogs at competitive prices. This accessibility allows more patients to manage their diabetes effectively, contributing to better health outcomes. The growing prevalence of diabetes, coupled with advancements in insulin formulations, reinforces the market's expansion, making insulin therapy more attainable for a larger segment of the population.

For instance, in June 2025, The CDSCO in India has given Eli Lilly approval to distribute Tirzepatide-based Mounjaro, a drug to treat type 2 diabetes, in the country. Such initiatives are accelerating the diabetes care market revenue.

Increased Healthcare Expenditure in Japan

The diabetes care market in Japan is significantly influenced by rising healthcare expenditure, which reflects the country's commitment to effectively managing this chronic disease. This investment is crucial in addressing the growing prevalence of diabetes, particularly among the aging population, and enhancing the quality of care available to patients.

For instance, in May 2025, Sumitomo Pharma Co., Ltd. announced that Sumitomo Pharma and Novo Nordisk Pharma Ltd. have entered into a co-promotion agreement (hereinafter referred to as "this agreement") in Japan for Ozempic® Subcutaneous Injection 2 mg, a once-weekly subcutaneous GLP-1 receptor agonist indicated for the treatment of type 2 diabetes.

Market Concentration and Competitive Landscape

To learn more about this report, Download Free Sample

Key Takeaways from Analyst

• The diabetes care market is poised for strong growth driven by the rising global prevalence of diabetes. Growing obese and geriatric populations are major drivers contributing to the increased diabetes burden. Furthermore, affluent lifestyles and changing dietary patterns have heightened the risk of developing diabetes.
• Reimbursement issues in some regions coupled with the economic slowdown due to the ongoing pandemic can hamper market growth to an extent. Privacy and data protection challenges pertaining to digital health solutions also act as a restraining factor.
• North America is expected to dominate in the diabetes care industry supported by high healthcare expenditures and accessibility to advanced products. However, Asia Pacific is likely to emerge as the fastest growing region due to its huge diabetic population pool and increasing healthcare investments in major countries like China and India.

Diabetes Care Market News

• In March 2025, Morepen Laboratories Limited introduced Empamore, a breakthrough therapy designed to treat Type 2 Diabetes Mellitus (T2DM), Heart Failure with Reduced Ejection Fraction (HFrEF), and Chronic Kidney Disease (CKD).
• In April 2025, International Diabetes Federation (IDF) launched the new IDF Global Clinical Practice Recommendations for the Management of Type 2 Diabetes at the World Diabetes Congress IDF 2025 in Bangkok, Thailand.
• In December 2024, the American Diabetes Association® released the Standards of Care in Diabetes—2025 (Standards of Care) the gold standard in evidence-based guidelines for diagnosing and managing diabetes and prediabetes. 

Market Report Scope

Diabetes Care Market Report Coverage

Market Dynamics

Diabetes Care Market Growth Driver - Rising demand for advanced treatment devices

Continuous glucose monitoring (CGM) systems and insulin pumps have revolutionized treatment, shifting from basic blood sugar monitoring to precise, data-driven regimens. CGM devices, in particular, provide real-time glucose tracking and alerts for critical levels, enabling proactive responses to fluctuations. With smaller, cost-effective options emerging, CGM adoption is accelerating across various demographics, enhancing patient outcomes and quality of life. Constant innovation is thus fueling growth of diabetes care industry and enabling higher quality care through minimally invasive monitoring and treatment methods.

Diabetes Care Market Opportunity - Growing popularity of continuous glucose monitoring devices

The diabetes care market has a room to grow, and one big opportunity is the growing acceptance and demand for continuous glucose monitoring (CGM) devices. These systems give glucose readings in almost real time without the need for finger pricks, which makes them more convenient for users. The increasing use of CGMs is due to improvements in technology, such as smaller sensors and longer wear times, which make patients happier and more likely to follow the rules.

Market Segmentation

• Product Type Insights (Revenue, USD Bn, 2020 - 2032)
• Glucose Monitoring Devices
• Blood glucose monitoring (BGM)
• Continuous glucose monitoring (CGM)
• Flash glucose monitoring (FGM)
• Insulin Pumps
• Patch pump
• Tethered pump
• Implanted insulin pump
• Others (Insulin Syringes, Pen Needles, etc.)
• Diabetes Type Insights (Revenue, USD Bn, 2020 - 2032)
• Type 2 Diabetes
• Type 1 Diabetes
• Other (Gestational Diabetes, etc.)
• End User Insights (Revenue, USD Bn, 2020 - 2032)
• Hospitals & Clinics
• Homecare Settings
• Ambulatory Care Settings
• Others (Academic and Research Institutes, Clinical Laboratories, etc.)
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• Medtronic
• Abbott
• Pumps It, Inc.
• Embecta Corp
• Insulet Corporation
• Ypsomed AG
• Roche AG
• Tandem Diabetes Care, Inc.
• Terumo
• Novo Nordisk A/S
• SOOIL Developments Co., Ltd
• Microtec Medical Ltd
• ViCentra B.V.
• CeQur Corporation
• Dexcom, Inc.

Sources

Primary Research Interviews

• Healthcare professionals and endocrinologists
• Diabetes care device manufacturers and suppliers
• Healthcare facility administrators and diabetes clinic managers
• Patients and caregivers using diabetes management solutions
• Others

Databases

• IMS Health Database
• IQVIA Healthcare Database
• Global Health Observatory (WHO) Database
• Healthcare Cost and Utilization Project (HCUP) Database
• Others

Magazines

• Diabetes Forecast Magazine
• Diabetes Self-Management Magazine
• Clinical Diabetes Magazine
• Diabetes Care Technology Magazine
• Others

Journals

• Diabetes Care Journal
• Journal of Diabetes Science and Technology
• Diabetologia Journal
• Others

Newspapers

• The Wall Street Journal (Healthcare Section)
• Reuters Health News
• Bloomberg Healthcare
• Financial Times (Healthcare Coverage)
• Others

Associations

• American Diabetes Association (ADA)
• International Diabetes Federation (IDF)
• Juvenile Diabetes Research Foundation (JDRF)
• European Association for the Study of Diabetes (EASD)
• Others

Public Domain Sources

• Centers for Disease Control and Prevention (CDC)
• World Health Organization (WHO) Reports
• U.S. Food and Drug Administration (FDA) Publications
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Others

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of information for last 8 years